Company profile

Partner Therapeutics, Inc.

partnertx.comHeadquarters: United States
51-200 employeesHybrid (Product + Service)
Partner Therapeutics, Inc. logo

Primary focus

Development, manufacturing and commercialization of late-stage biologic therapeutics, with emphasis on oncology, immunomodulation and medical countermeasures.

Why it’s included

The profile explicitly states that Partner Therapeutics develops and manufactures Leukine (sargramostim), which is FDA-approved for treating hematological damage due to acute radiation exposure, and cites BARDA funding for its advanced development as a medical countermeasure for radiation injury.

Relevant capabilities

  • Host-directed immunomodulatory therapy development (recombinant GM-CSF)
  • Preclinical in vivo efficacy models and animal studies
  • GMP-compliant biologics manufacturing and facility operation
  • Development and commercialization of late-stage biologic therapeutics
  • Scale-up and expansion of manufacturing capacity for surge demand
Commercial sectorHematopoietic & Systemic ARS Countermeasure Therapeutics
Technology classesHematopoietic growth factor biologics (G-CSF, GM-CSF)

Relevant commercial products

  • Leukine (sargramostim)
  • IMREPLYS
  • Zenocutuzumab (targeted antibody for NRG1 fusion-positive cancers)
  • BIZENGRI

← Back to what’s inside this report